Decoding Humoral Response: AI Unlocking B Cells to Predict Cancer Immunotherapy's Double-Edged Sword

AI decodes B cell repertoires, predicting cancer immunotherapy outcomes and toxicity, transforming precision oncology.

Ailurus Press
August 28, 2025
. https://www.science.org/doi/10.1126/sciadv.abq5089
  • A unified cross-attention model for predicting antigen binding specificity to both HLA and TCR molecules. (2024). arXiv. https://arxiv.org/html/2405.06653
  • A Pan-Cancer Analysis of Tumor-Infiltrating B Cell Repertoires. (2022). Frontiers in Immunology. https://pmc.ncbi.nlm.nih.gov/articles/PMC8767103/
  • B-cell receptor repertoire sequencing: Deeper digging into the mechanisms and clinical aspects of immune-mediated diseases. (2022). Frontiers in Immunology. https://pmc.ncbi.nlm.nih.gov/articles/PMC9494237/
  • Prediction of checkpoint inhibitor immunotherapy efficacy for cancer using routine blood tests and clinical data. (2024). Nature Medicine. https://www.nature.com/articles/s41591-024-03398-5
  • A blueprint for tumor-infiltrating B cells across human cancers. (2024). Science. https://www.science.org/doi/10.1126/science.adj4857
  • About Ailurus

    Ailurus Bio is a pioneering company building biological programs, genetic instructions that act as living software to orchestrate biology. We develop foundational DNAs and libraries, transforming lab-grown cells into living instruments that streamline complex research and production workflows. We empower scientists and developers worldwide with these bioprograms, accelerating discovery and diverse applications. Our mission is to make biology the truly general-purpose technology, as programmable and accessible as modern computers, by constructing a biocomputer architecture for all.

    For more information, visit: ailurus.bio
    Share this post

    Recent posts

    Subscribe and get new posts and updates from Ailurus.

    Subscribe